P46373 10th Annual Biomanufacturing
Download Brochure Request

Register your interest


Register your interest


10th Annual Biomanufacturing

18 – 20 May 2020, Shanghai, China

Book Now Download Brochure



The future of biomanufacturing is set for a revolution. New outsourcing trends, mass customisaton and precision medicine, intensification versus continuous models, and the rise of intelligent facilities, are but some of the issues driving the change. Smart biomanufacturing is increasingly playing a crucial role in fulfilling the needs of the market.

Further, as China’s MAH programme takes root, it is expected to give a major boost to the CMO market. IBC’s 9th Biomanufacturing Summit in China comes back as part of the BDP Week, comprising of 5 collocated events. It will justify your investment by offering debates, insights, learning seminars and networking with an unrivalled gathering of the biotech industry.

Discussion themes

  • Clinical and commercial phase market outlook for CMOs in China
  • Projecting impacts of the MAH programme
  • Capacity outlook – utilization rates, new investment and a medium term position
  • CMO pricing trends
  • Big Pharma insights on market segments driving new growth
  • Capitalising on the MaB therapeutics market
  • Smart Biomanufacturing – trends, investment and case studies
  • Automation and digitalisation trends
  • AI in Biomanufacturing – key components, and use cases
  • Case studies in Small scale, smart and flexible manufacturing systems and processes
  • Intelligent bio reactors, advantages, workings and benefits
  • Trends and best practice dominating Process intensification and Continuous manufacturing
  • Single use strategy and implementation
  • Staffing and skilling strategies
  • The latest in tech and equipment from top vendors, and how they are being implemented


For more information, visit www.biopharmaproduction.com >>


8:00 am

Main Conference Registration and Morning Coffee

9:00 am

Chairperson’s Opening Remarks

Judith Li, Partner, Lilly Asia Ventures, Hong Kong


9:05 am

Investor Talk by Lilly Asia Ventures: China’s Great Leap Forward in Biotech

Judith Li, Partner, Lilly Asia Ventures, Hong Kong

9:30 am

  • Recent regulatory developments – obstacle or opportunity?
  • The clinical trials market
  • China market scenarios on CAR-T & CRISPR technology
  • Growth prospects on cell line development market and therapeutics
  • Current state of affairs on biosimilars
  • Digitalization of biopharma value chain – is China ahead of the game?
  • How are new business models creating opportunities?

10:30 am

Morning Networking and Refreshment Break


11:20 am

Chairperson’s Opening Remarks

Dr Junli Zhang, Senior Vice President & Chief Operating Officer, Shanghai Henlius Biotech, Inc.


11:30 am

  • Evaluating new tech platforms for commercial manufacturing
  • Where do we see the shift in digitalisation in China?
  • Tech transfer, single-use, and manufacturing process control
  • A case study of open-access technology platform

12:00 pm

Promoting Scalability by Bioprocessing in a Flexible, Open, and Agile Automation Platform

Jason Lukasek, Senior Director, BEA, BPD Commercial, Thermo Fisher Scientific

12:30 pm

Networking Lunch

1:30 pm

  • Key points on digital transformation – Embracing the change in process, technology and human resource
  • Meeting the demand of global pharmaceutical market and China’s role in speed-to-market
  • The emergence of CDMOs and their tech capabilities in China
  • Evaluating digital strategy in China and building smart facilities
  • Digital transformation in vaccines, mAbs, and biologics manufacturing
  • Automation and digitalisation trends


2:10 pm

Trends in Biotechnologies - Continuous Processing Update

David Johnson, Senior Global Product Manager, Pall Biotech

2:40 pm

  • Working with NMPA’s requirement on MGP standards and manufacturing compliance
  • EU requirement – Facility design and manufacturing processes
  • One-off production technology in both upstream and downstream for biosimilars
  • How Henlius is adopting facility of future and latest technologies?

3:10 pm

Afternoon Networking & Refreshment Break

3:40 pm

High Efficient Perfusion Bioprocess Introduction

Liu Changjun, Product Manager, GE


5:30 pm

Chairperson’s Summary and End of Main Conference Day One

8:55 am

Chairperson’s Opening Remarks

Dr Jerry Dong, Vice President of CMC and Regulatory Affairs, Shanghai Henlius Biotech, Inc.


9:10 am

  • Feasibility analysis on single-use facilities
  • How to implement single-use solution to optimize up-streaming processing
  • Advantages and feasibility of single-use solutions in down-streaming separation and purification

9:50 am

  • Minimizing initial investment and time to the clinic – early phase product strategy
  • Establishing a commercially viable process up front avoid costly rework and delay
  • Ensuring continuous supply in both clinical and commercial lifecycle
  • Approaching process development program and streamlined tech transfer

10:30 am

Morning Networking and Refreshment Break

11:10 am

  • Working with QC and QA oversight and operations, Quality Systems, regulatory guidelines and requirements
  • CMC development from pre-clinical to market filing
  • Working with CROs and CMOs to achieve quality products
  • Case study of CMC development of biologics from preclinical to commercial launch and post-commercial support

11:50 am

Internationalisation of Local Manufactured Drugs through Quality and Manufacturing Excellence

Michelle Peake, Senior General Manager, PT Kalbio Global Medika, Indonesia

12:30 pm

Networking Lunch

1:30 pm

  • How QbD is changing the landscape of biopharma manufacturing?
  • Managing manufacturing risk assessment, process analytical technology (PAT) implementation of large scale continuous manufacturing
  • Managing manufacturing costs
  • Meeting GMP standards and manufacturing excellence

2:00 pm

  • The trend in biologics development and manufacturing needs
  • Update on disposable continuous manufacturing GMP facilities
  • Implementation case study of an antibody continuous processing manufacturing facility
  • Facility investment trends


2:30 pm

Advances in Magnetic Bead Antibody Purification

John K. Kawooya, Director, Biologics Optimization, Amgen, Inc.

3:00 pm

  • Operations for an autologous cell therapy
  • Case study for scaling up
  • Challenges in utilising different cell types such as bi-specific CAR-T cells, regulatory T cells and hematopoietic stem cells
  • Implementing automated solutions across the cell and gene therapy manufacturing pathway.
  • Key processing challenges for cell and gene therapy products

3:30 pm

Afternoon Networking & Refreshment Break


5:00 pm

Chairperson’s Summary and End of the Conference

9:00 am

China’s biopharma industry continues to grow rapidly  and hails as a major investment region in the world. With tides of tech innovation, market growth in CRO, CMO and CDMO, a numerous clinical trials projects lined-up, newly discovered therapies to the market and upgrading manufacturing facilities to name a few. This workshop aims to provide a strategic snapshot of the investment landscape for biopharma medicine, and covers practical aspects on how biotech companies can navigate the investment and pricing options for related drugs and treatments to generate better returns.

You will learn:

  • Financing clinical trials operations
  • R&D investment and financing models
  • Manufacturing financing
  • Financial partnership with Chinese pharma and biotech
  • Biosimilars products financing
  • Going Public and Listing insights
  • Deal, debt and equity structuring

1:00 pm

End of Workshop


Packages Price
2 Day Conference - International Companies, Global HQ Located Outside ChinaUS $1895US $1695Early BirdEarly Bird
Group of 2 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1495Early Bird
Group of 4 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1295Early Bird
2 Day Conference - Local China CompaniesUS $977US $827Early BirdEarly Bird
Group of 2 or more delegates - Local China CompaniesUS $752Early Bird
Group of 4 or more delegates - Local China CompaniesUS $676Early Bird
Extras Price
Pre Conference Workshop - International Companies, Global HQ Located Outside China US $300
Pre Conference Workshop - Local China Companies US $150
Gala Dinner US $50

Early Bird Rate: Register & Pay by 27 March 2020

  • Multiple Bookings Discount pricing is applicable to groups of 2 or more delegates from the same organisation registering for the same event, at the same time.
  • Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR group rate.
  • All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
  • All delegates from Singapore-based companies are required to pay an additional 7% GST (SINGAPORE EVENTS ONLY)
  • View payment terms and bank transfer details, click here »

CNY Pricing

  • 2 Day Conference: CNY 6,500
  • Group of 2 or more delegates: CNY 5,000
  • Group of 4 or more delegates: CNY 4,500
  • Pre Conference Workshop: CNY 1,000
  • Gala Dinner: CNY 350


Partnership and Profile Building Opportunities are Now Available!
Contact us today to find out how you can position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available.


Judith Li

Partner, Lilly Asia Ventures, Hong Kong

Feng Tao

Founding Partner, Biotrack Capital, China

He Ting

Chief Executive Officer, ImmunoChina, China

Dong Wei

CEO, Edigene, China

Peter Luo

CEO, Adagene Pharma, China

Jonathan Zhao 4th Annual Bioprocess and Technology 2018

Jonathan Zhao

Co-Founder and Executive Chairman, TRANSCENTA HOLDING, China

Dr Junli Zhang

Senior Vice President & Chief Operating Officer, Shanghai Henlius Biotech, Inc.

Dr. Jimmy Li

Vice President & Head of Manufacturing Facility 1 of Wuxi Site, Wuxi Biologics, China

Jason Lukasek

Senior Director, BEA, BPD Commercial, Thermo Fisher Scientific

Dr. Xiangyang Zhu

Chief Executive Officer, Huabo Biopharma, China

Dr Peter Pang

General Manager, XiKang (Wuhan) Biopharmaceutical Co.Ltd., EVP, Corporate Head of Regulatory Affairs, JHL Biotech Inc, China

Dr. Jerry Yang

Senior Vice President, Process & Product Development, Hangzhou JUST Biotherapeutics, China

David Johnson

Senior Global Product Manager, Pall Biotech

Liu Changjun

Product Manager, GE

Dr. Qinghai Zhao

Vice President, Technical Development and Manufacturing, Forty-Seven Inc. USA

Wenzhi Tian

MD, Chairman & CEO, ImmuneOnco Biopharma Co., Ltd, China

Dr Jerry Dong

Vice President of CMC and Regulatory Affairs, Shanghai Henlius Biotech, Inc.

Dr Zack Zheng

Vice President of Manufacturing and Technology, JHL Biotech, China

Rhona McIntyre

Associate Director Commercial Development, Lonza Pharma & Biotech

Michelle Peake

Senior General Manager, PT Kalbio Global Medika, Indonesia

David Jan

SVP Manufacturing Operations, Zhejiang Teruisi Biopharmaceutical, China

John K. Kawooya

Director, Biologics Optimization, Amgen, Inc.

Dr. Lin Yang

Chief Executive Officer, PersonGen Biomedicine, China

Chen-Yuan Lin

Ward Director and Attending Physician at the Division of Hematology and Oncology, China Medical University Hospital, Taiwan

Dr Lin Shiwen

Vice President of Downstream Process Development, WuXi Biologics, China

Xiaodi Su

Senior Investment Manager, Lilly Asia Ventures, China

Jieyu Zou

Vice President, Lilly Asia Ventures, China

when & where

18 - 20 May 2020


Still have a question?


IBC Asia is Singapore's leading event organiser. We conceive, develop and promote our own B2B industry conferences and corporate training courses, and offer tailored managed event solutions.

Find out more

We are changing our brand to Informa Connect
Learn More